HER majesty's a pretty nice girl but she changes from day to day

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages 465-466

  Bohanes, Pierre ^a   Loupakis, Fotios ^a   Labonte, Melissa J ^a   Wakatsuki, Takeru ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; ENDOXIFEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN;

LETTER; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL;

CARCINOMA; FEMALE; HUMANS; MALE; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856712045     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.4098     Document Type: Letter

References (9)

1. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
2. Terashima M, Ochiai A, Kitada K, et al: Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. J Clin Oncol 29:259s, 2011 (suppl; abstr 4013)
3. Hayashi M, Inokuchi M, Takagi Y, et al: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14:7843-7849, 2008
4. Kim MA, Lee HS, Lee HE, et al: EGFR in gastric carcinomas: Prognostic significance of protein overexpression and high gene copy number. Histopathology 52:738-746, 2008 (Pubitemid 351600058)
5. Galizia G, Lieto E, Orditura M, et al: Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31:1458-1468, 2007 (Pubitemid 46945355)
6. Maresch J, Schoppmann SF, Thallinger CM, et al: Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment. Crit Rev Oncol Hematol 10.1016/j critrevonc.2011.06.003 [epub ahead of print on July 21, 2011]
7. Begnami MD, Fukuda E, Fregnani JH, et al: Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29:3030-3036, 2011
8. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
9. Shah MA, Janjigian YY, Pauligk C, et al: Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis. J Clin Oncol 29:259s, 2011 (suppl; abstr 4014)